Cargando…

Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Athyros, Vasilios G, Mikhailidis, Dimitri P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468870/ https://www.ncbi.nlm.nih.gov/pubmed/23066433 http://dx.doi.org/10.2174/1874192401206010122

Ejemplares similares

Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters
por: Dayspring, Thomas D
Publicado: (2011)

ODP155 Successful Treatment of PEG-Asparaginase Related Hypertriglyceridemia with Omega-3 Acid Ethyl Esters
por: Radovanovic, Natasa, et al.
Publicado: (2022)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Effect of Omega-3 Fatty Acid Ethyl Esters on the Oxylipin Composition of Lipoproteins in Hypertriglyceridemic, Statin-Treated Subjects
por: Newman, John W., et al.
Publicado: (2014)

Microalgal feedstock for the production of omega-3 fatty acid ethyl esters and ɛ-polylysine
por: Sivaramakrishnan, Ramachandran, et al.
Publicado: (2021)

Omega-3 Fatty Acid Based Nanolipid Formulation of Atorvastatin for Treating Hyperlipidemia
por: Sreedhar, Revathy, et al.
Publicado: (2019)

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
por: Backes, James, et al.
Publicado: (2016)

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters
por: Furuhashi, Masato, et al.
Publicado: (2016)

Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia
por: Han, Eugene, et al.
Publicado: (2016)

Is There a Role for Hypolipidaemic Drug Therapy in the Prevention or Treatment of Microvascular Complications of Diabetes?
por: Mitsiou, Eydoxia K, et al.
Publicado: (2012)

Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial
por: Qi, Litong, et al.
Publicado: (2021)

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
por: Tziomalos, Konstantinos, et al.
Publicado: (2011)

Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
por: Pirillo, Angela, et al.
Publicado: (2015)

Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial
por: Chevalier, Laurie, et al.
Publicado: (2020)

A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study
por: Maki, Kevin C., et al.
Publicado: (2022)

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
por: Kim, Jae Hoon, et al.
Publicado: (2022)

Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial
por: Chevalier, Laurie, et al.
Publicado: (2021)

Treatment of Severe Hypertriglyceridemia During Pregnancy With High Doses of Omega-3 Fatty Acid and Plasmapheresis
por: Nguyen, Nguyen T., et al.
Publicado: (2021)

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl
por: Hassan, Amir, et al.
Publicado: (2014)

Omega-3 Fatty Acid Ethyl Esters do not Improve Clopidogrel Associated P2Y12 Inhibition in Stroke Patients
por: Li, Ping, et al.
Publicado: (2015)

Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease
por: Levantesi, Giacomo, et al.
Publicado: (2010)

Adverse effects of ethyl esters or oxidation products in omega-3 preparations?
por: Rupp, Heinz, et al.
Publicado: (2014)

The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings
por: Athyros, Vasilios G., et al.
Publicado: (2012)

Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?
por: Athyros, Vasilios G., et al.
Publicado: (2011)

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
por: Krysiak, Robert, et al.
Publicado: (2011)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Engineering oleaginous yeast Rhodotorula toruloides for overproduction of fatty acid ethyl esters
por: Zhang, Yang, et al.
Publicado: (2021)

Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Jun, Ji Eun, et al.
Publicado: (2020)

A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
por: Karalis, Dean G.
Publicado: (2016)

Limited Impact of 2 g/day Omega-3 Fatty Acid Ethyl Esters (Omacor(®)) on Plasma Lipids and Inflammatory Markers in Patients Awaiting Carotid Endarterectomy
por: Yusof, Hayati M., et al.
Publicado: (2013)

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients
por: Su, Ta-Chen, et al.
Publicado: (2017)

The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms
por: Kolovou, Genovefa D, et al.
Publicado: (2009)

New Therapy Using Omega-3-Acid Ethyl Esters for Decubitus Ulcers and Stasis Dermatitis: A Case Report
por: Nagai, Kazuki, et al.
Publicado: (2014)

CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis
por: Prentice, Kacey J., et al.
Publicado: (2017)

Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial
por: Sheikh, Omar, et al.
Publicado: (2019)

Omega 3 Fatty Acids vs Omega 6 Fatty Acids
por: Feliu, María, et al.
Publicado: (2022)

Omega-3 Fatty Acids Improve Chronic Kidney Disease—Associated Pruritus and Inflammation
por: Lin, Ya-Ling, et al.
Publicado: (2022)

Placental Fatty Acid Ethyl Esters Are Elevated with Maternal Alcohol Use in Pregnancies Complicated by Prematurity
por: Gauthier, Theresa W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6grr0p9hd1epg69cuk30s4u58p